An exposure: Activity profiling method for interpreting high-throughput screening data for estrogenic activity-Proof of concept

Regulatory Toxicology and Pharmacology

Volumn 71, Issue 3, 2015, Pages 398-408

  Becker, Richard A ^a   Friedman, Katie Paul ^b   Simon, Ted W ^c   Marty, M Sue ^d   Patlewicz, Grace ^e,f   Rowlands, J Craig ^d  

^a American Chemistry Council   (United States)

^b BAYER CROPSCIENCE   (United States)

^c Ted Simon LLC   (United States)

^d DOW CHEMICAL COMPANY   (United States)

^e DUPONT COMPANY   (United States)

^f U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Endocrine disruption; Estrogen assays; Exposure; Exposure:activity ratio; Genistein; Potency; Relative estrogenic exposure:activity quotient; Tox21; ToxCast

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; BENFLURALIN; BENSULIDE; BIFENTHRIN; BOSCALID; CHLORPYRIFOS METHYL; CLOMAZONE; CYPROCONAZOLE; CYPRODINIL; DICOFOL; DIPHENYLAMINE; DISULFOTON; ENDOSULFAN; ENVIRONMENTAL CHEMICAL; ETHAFLURALIN; FENAMIDONE; FENARIMOL; FENBUCONAZOLE; FENHEXAMID; FENVALERATE; FLUSILAZOLE; GENISTEIN; METOLACHLOR; MYCLOBUTANIL; OXYFLUORFEN; PENDIMETHALIN; PERMETHRIN; PHYTOESTROGEN; TEFLUTHRIN; TRIFLURALIN; UNCLASSIFIED DRUG; ENDOCRINE DISRUPTOR; ESTROGEN; ESTROGEN RECEPTOR;

ARTICLE; COMPUTER PROGRAM; DECISION MAKING; DRUG ACTIVITY; DRUG DETERMINATION; DRUG EXPOSURE; ESTROGEN ACTIVITY; EXPOSURE ACTIVITY RATIO; HEALTH HAZARD; HIGH THROUGHPUT SCREENING; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; COMPARATIVE STUDY; DECISION SUPPORT SYSTEM; DOSE RESPONSE; DRUG EFFECTS; HUMAN; METABOLISM; PROCEDURES; REPRODUCIBILITY; RISK ASSESSMENT; SIGNAL TRANSDUCTION; STANDARDS; TOXICITY TESTING;

DECISION SUPPORT TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCRINE DISRUPTORS; ESTROGENS; GENISTEIN; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PHYTOESTROGENS; RECEPTORS, ESTROGEN; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TOXICITY TESTS;

EID: 84923268093     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2015.01.008     Document Type: Article

References (85)

1. Aarts J.M.M.J.G., Wang S., Houtman R., van Beuningen R.M.G.J., Westerink W.M.A., Van De Waart B.J., Rietjens I.M.C.M., Bovee T.F.H. Robust array-based coregulator binding assay predicting ERα-agonist potency and generating binding profiles reflecting ligand structure. Chem. Res. Toxicol. 2013, 26:336-346. 10.1021/tx300463b.
2. Avbersek M., Somen J., Heath E. Dynamics of steroid estrogen daily concentrations in hospital effluent and connected waste water treatment plant. J. Environ. Monitor.: JEM 2011, 13(8):2221-2226. 10.1039/c1em10147a.
3. Arai Y., Uehara M., Sato Y., Kimira M., Eboshida A., Adlercreutz H., Watanabe S. Comparison of isoflavones among dietary intake, plasma concentration and urinary excretion for accurate estimation of phytoestrogen intake. J. Epidemiol. 2000, 10:127-135.
4. Armitage J.M., Wania F., Arnot J.A. Application of mass balance models and the chemical activity concept to facilitate the use of in vitro toxicity data for risk assessment. Environ. Sci. Technol. 2014, [Epub ahead of print].
5. Becker R.A., Hays S.M., Kirman C.R., Aylward L.L., Wise K. Interpreting estrogen screening assays in the context of potency and human exposure relative to natural exposures to phytoestrogens. Birth. Defects. Res. B. Dev. Reprod. Toxicol. 2014, 10.1002/bdrb.21085.
6. Bermudez D.S., Gray L.E., Wilson V.S. Modeling the interaction of binary and ternary mixtures of estradiol with Bisphenol A and Bisphenol AF in an in vitro estrogen-mediated transcriptional activation assay (T47D-KBluc). Toxicol. Sci.: off. J. Soc. Toxicol. 2010, 116(2):477-487. 10.1093/toxsci/kfq156.
7. Bermudez D.S., Gray L.E., Wilson V.S. Modelling defined mixtures of environmental oestrogens found in domestic animal and sewage treatment effluents using an in vitro oestrogen-mediated transcriptional activation assay (T47D-KBluc). Int. J. Androl. 2012, 35:397-406. 10.1111/j.1365-2605.2012.01278.x.
8. Borgert C.J., Sargent E.V., Casella G., Dietrich D.R., McCarty L.S., Golden R.J. The human relevant potency threshold: reducing uncertainty by human calibration of cumulative risk assessments. Regul. Toxicol. Pharmacol. 2012, 62:313-328. 10.1016/j.yrtph.2011.10.012.
9. Borgert C.J., Baker S.P., Matthews J.C. Potency matters: thresholds govern endocrine activity. Regul. Toxicol. Pharmacol. 2013, 67:83-88. 10.1016/j.yrtph.2013.06.007.
10. Busby M.G., Jeffcoat A.R., Bloedon L.T., Koch M.A., Black T., Dix K.J., Heizer W.D., Thomas B.F., Hill J.M., Crowell J.A., Zeisel S.H. Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am. J. Clin. Nutr. 2002, 75:126-136.
11. Chow C.C., Ong K.M., Dougherty E.J., Simons S.S. Inferring mechanisms from dose-response curves. Methods Enzymol. 2011, 487:465-483. 10.1016/B978-0-12-381270-4.00016-0.
12. Cimino C.O., Shelnutt S.R., Ronis M.J., Badger T.M. An LC-MS method to determine concentrations of isoflavones and their sulfate and glucuronide conjugates in urine. Clin. Chim. Acta 1999, 287:69-82.
13. Cox L.A.T., Popken D., Marty M.S., Rowlands J.C., Patlewicz G., Goyak K.O., Becker R.A. Developing scientific confidence in HTS-derived prediction models: lessons learned from an endocrine case study. Regul. Toxicol. Pharmacol. 2014, 69:443-450. 10.1016/j.yrtph.2014.05.010.
14. Crofton K.M. Thyroid disrupting chemicals: mechanisms and mixtures. Int. J. Androl. 2008, 31:209-223.
15. Crozier A., Clifford M.N., Ashihara H. Plant Secondary Metabolites, Occurrence, Structure and Role in the Human Diet 2006, Blackwell Publishing Ltd., Oxford, U.K.
16. Doerge D.R., Chang H.C. Inactivation of thyroid peroxidase by soy isoflavones, in vitro and in vivo. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2002, 777:269-279.
17. Duncan A.M., Underhill K.E., Xu X., Lavalleur J., Phipps W.R., Kurzer M.S. Modest hormonal effects of soy isoflavones in postmenopausal women. J. Clin. Endocrinol. Metab. 1999, 84:3479-3484.
18. Giesy J.P., Hilscherova K., Jones P.D., Kannan K., Machala M. Cell bioassays for detection of aryl hydrocarbon (AhR) and estrogen receptor (ER) mediated activity in environmental samples. Mar. Pollut. Bull. 2002, 45:3-16.
19. Grace P.B., Taylor J.I., Botting N.P., Fryatt T., Oldfield M.F., Al-Maharik N., Bingham S.A. Quantification of isoflavones and lignans in serum using isotope dilution liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2003, 17:1350-1357. 10.1002/rcm.1059.
20. Grace P.B., Taylor J.I., Low Y.-L., Luben R.N., Mulligan A.A., Botting N.P., Dowsett M., Welch A.A., Khaw K.-T., Wareham N.J., Day N.E., Bingham S.A. Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European prospective investigation of cancer and nutrition-norfolk. Cancer Epidemiol. Biomarkers Prev. 2004, 13:698-708.
21. Guillemette C., Bélanger A., Lépine J. Metabolic inactivation of estrogens in breast tissue by UDP-glucuronosyltransferase enzymes: an overview. Breast Cancer Res. 2004, 2004(6):246-254.
22. Hays S.M., Aylward L.L., LaKind J.S., Bartels M.J., Barton H.A., Boogaard P.J., Brunk C., DiZio S., Dourson M., Goldstein D.A., Lipscomb J., Kilpatrick M.E., Krewski D., Krishnan K., Nordberg M., Okino M., Tan Y.-M., Viau C., Yager J.W., Biomonitoring Equivalents Expert Workshop Guidelines for the derivation of biomonitoring equivalents: report from the biomonitoring equivalents expert workshop. Regul. Toxicol. Pharmacol. 2008, 51:S4-S15. 10.1016/j.yrtph.2008.05.004.
23. Heald C.L., Bolton-Smith C., Ritchie M.R., Morton M.S., Alexander F.E. Phyto-oestrogen intake in Scottish men: use of serum to validate a self-administered food-frequency questionnaire in older men. Eur. J. Clin. Nutr. 2006, 60:129-135. 10.1038/sj.ejcn.1602277.
24. Hosoda K., Furuta T., Ishii K. Metabolism and disposition of isoflavone conjugated metabolites in humans after ingestion of kinako. Drug Metab. Dispos. 2011, 39:1762-1767. 10.1124/dmd.111.038281.
25. Houtman R., de Leeuw R., Rondaij M., Melchers D., Verwoerd D., Ruijtenbeek R., Martens J.W.M., Neefjes J., Michalides R. Serine-305 phosphorylation modulates estrogen receptor alpha binding to a coregulator peptide array, with potential application in predicting responses to tamoxifen. Mol. Cancer Ther. 2012, 11:805-816. 10.1158/1535-7163.MCT-11-0855.
26. Iwasaki M., Inoue M., Otani T., Sasazuki S., Kurahashi N., Miura T., Yamamoto S., Tsugane S., Japan Public Health Center-based prospective study group Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case-control study from the Japan Public Health Center-based prospective study group. J. Clin. Oncol. 2008, 26:1677-1683. 10.1200/JCO.2007.13.9964.
27. Jarosova B., Blaha L., Giesy J.P., Hilscherova K. What level of estrogenic activity determined by in vitro assays in municipal waste waters can be considered as safe?. Environ. Int. 2014, 64:98-109. 10.1016/j.envint.2013.12.009.
28. Jeyakumar M., Webb P., Baxter J.D., Scanlan T.S., Katzenellenbogen J.A. Quantification of ligand-regulated nuclear receptor corepressor and coactivator binding, key interactions determining ligand potency and efficacy for the thyroid hormone receptor. Biochemistry 2008, 47:7465-7476. 10.1021/bi800393u.
29. Jeyakumar M., Carlson K.E., Gunther J.R., Katzenellenbogen J.A. Exploration of dimensions of estrogen potency: parsing ligand binding and coactivator binding affinities. J. Biol. Chem. 2011, 286:12971-12982. 10.1074/jbc.M110.205112.
30. Judson R., Houck K., Martin M., Knudsen T., Thomas R.S., Sipes N., Shah I., Wambaugh J., Crofton K. In vitro and modelling approaches to risk assessment from the U.S. Environmental Protection Agency ToxCast Programme. Basic Clin. Pharmacol. Toxicol. 2014, 115:69-76. 10.1111/bcpt.12239.
31. Judson R.S., Houck K.A., Kavlock R.J., Knudsen T.B., Martin M.T., Mortensen H.M., Reif D.M., Rotroff D.M., Shah I., Richard A.M., Dix D.J. In vitro screening of environmental chemicals for targeted testing prioritization: the ToxCast project. Environ. Health Perspect. 2010, 118:485-492. 10.1289/ehp.0901392.
32. Judson R.S., Kavlock R.J., Setzer R.W., Hubal E.A.C., Martin M.T., Knudsen T.B., Houck K.A., Thomas R.S., Wetmore B.A., Dix D.J. Estimating toxicity-related biological pathway altering doses for high-throughput chemical risk assessment. Chem. Res. Toxicol. 2011, 24:451-462. 10.1021/tx100428e.
33. Kraus W.L., Weis K.E., Katzenellenbogen B.S. Inhibitory cross-talk between steroid hormone receptors: differential targeting of estrogen receptor in the repression of its transcriptional activity by agonist- and antagonist-occupied progestin receptors. Mol. Cell. Biol. 1995, 15:1847-1857.
34. LaKind J.S., Aylward L.L., Brunk C., DiZio S., Dourson M., Goldstein D.A., Kilpatrick M.E., Krewski D., Bartels M.J., Barton H.A., Boogaard P.J., Lipscomb J., Krishnan K., Nordberg M., Okino M., Tan Y.-M., Viau C., Yager J.W., Hays S.M., Biomonitoring Equivalents Expert Workshop Guidelines for the communication of Biomonitoring Equivalents: report from the Biomonitoring Equivalents Expert Workshop. Regul. Toxicol. Pharmacol. 2008, 51:S16-S26. 10.1016/j.yrtph.2008.05.007.
35. Le H.T., Schaldach C.M., Firestone G.L., Bjeldanes L.F. Plant-derived 3,3'-Diindolylmethane is a strong androgen antagonist in human prostate cancer cells. J. Biol. Chem. 2003, 278(23):21136-21145.
36. Liu K.-C., Wu R.S.S., Ge W. Luteinizing hormone receptor (lhcgr) as a marker gene for characterizing estrogenic endocrine-disrupting chemicals in zebrafish ovarian follicle cells. Gen. Comp. Endocrinol. 2013, 192:89-94. 10.1016/j.ygcen.2013.06.023.
37. Metzner J.E., Frank T., Kunz I., Burger D., Riegger C. Study on the pharmacokinetics of synthetic genistein after multiple oral intake in post-menopausal women. Arzneimittelforschung 2009, 59:513-520.
38. Morgan R.E., van Staden C.J., Chen Y., Kalyanaraman N., Kalanzi J., Dunn R.T., Afshari C.A., Hamadeh H.K. A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol. Sci. 2013, 136:216-241. 10.1093/toxsci/kft176.
39. Murk A.J., Rijntjes E., Blaauboer B.J., Clewell R., Crofton K.M., Dingemans M.M., Furlow J.D., Kavlock R., Kohrle J., Opitz R., Traas T., Visser T.J., Xia M., Gutleb A.C. Mechanism-based testing strategy using in vitro approaches for identification of thyroid hormone disrupting chemicals. Toxicol. In Vitro 2013, 27:1320-1346. (24).
40. National Research Council (NRC) Toxicity Testing in the 21st Century: A Vision and a Strategy 2007, National Academies Press, Washington, DC.
41. National Research Council (NRC) Science and Decisions: Advancing Risk Assessment 2009, National Academies Press, Washington, DC.
42. Ong K.M., Blackford J.A., Kagan B.L., Simons S.S., Chow C.C. A theoretical framework for gene induction and experimental comparisons. Proc. Natl. Acad. Sci. USA 2010, 107:7107-7112. 10.1073/pnas.0911095107.
43. Pastoor T.P., Bachman A.N., Bell D.R., Cohen S.M., Dellarco M., Dewhurst I.C., Doe J.E., Doerrer N.G., Embry M.R., Hines R.N., Moretto A., Phillips R.D., Rowlands J.C., Tanir J.Y., Wolf D.C., Boobis A.R. A 21st century roadmap for human health risk assessment. Crit. Rev. Toxicol. 2014, 44(Suppl. 3):1-5.
44. Patlewicz G., Simon T., Goyak K., Phillips R.D., Rowlands J.C., Seidel S., Becker R.A. Use and validation of HT/HC assays to support 21st century toxicity evaluations. Regul. Toxicol. Pharmacol. 2013, 65:259-268. 10.1016/j.yrtph.2012.12.008.
45. Paul K.B., Hedge J.M., Rotroff D.M., Hornung M.W., Crofton K.M., Simmons S.O. Development of a thyroperoxidase inhibition assay for high-throughput screening. Chem. Res. Toxicol. 2014, 27(3):387-399.
46. Reif D.M., Martin M.T., Tan S.W., Houck K.A., Judson R.S., Richard A.M., Knudsen T.B., Dix D.J., Kavlock R.J. Endocrine profiling and prioritization of environmental chemicals using ToxCast data. Environ. Health Perspect. 2010, 118:1714-1720. 10.1289/ehp.1002180.
47. Richelle M., Pridmore-Merten S., Bodenstab S., Enslen M., Offord E.A. Hydrolysis of isoflavone glycosides to aglycones by beta-glycosidase does not alter plasma and urine isoflavone pharmacokinetics in postmenopausal women. J. Nutr. 2002, 132:2587-2592.
48. Ritchie M.R., Morton M.S., Deighton N., Blake A., Cummings J.H. Plasma and urinary phyto-oestrogens as biomarkers of intake: validation by duplicate diet analysis. Br. J. Nutr. 2004, 91:447-457. 10.1079/BJN20031062.
49. Rotroff D.M., Wetmore B.A., Dix D.J., Ferguson S.S., Clewell H.J., Houck K.A., Lecluyse E.L., Andersen M.E., Judson R.S., Smith C.M., Sochaski M.A., Kavlock R.J., Boellmann F., Martin M.T., Reif D.M., Wambaugh J.F., Thomas R.S. Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicol Sci. 2010, 117(2):348-358. 10.1093/toxsci/kfq22.
50. Rotroff D.M., Dix D.J., Houck K.A., Knudsen T.B., Martin M.T., McLaurin K.W., Reif D.M., Crofton K.M., Singh A.V., Xia M., Huang R., Judson R.S. Using in vitro high throughput screening assays to identify potential endocrine-disrupting chemicals. Environ. Health Perspect. 2013, 121:7-14. 10.1289/ehp.1205065.
51. Rotroff D.M., Dix D.J., Houck K.A., Kavlock R.J., Knudsen T.B., Martin M.T., Reif D.M., Richard A.M., Sipes N.S., Abassi Y.A., Jin C., Stampfl M., Judson R.S. Real-time growth kinetics measuring hormone mimicry for ToxCast chemicals in T-47D human ductal carcinoma cells. Chem. Res. Toxicol. 2013, 26:1097-1107. 10.1021/tx400117y.
52. Rotroff D.M., Martin M.T., Dix D.J., Filer D.L., Houck K.A., Knudsen T.B., Sipes N.S., Reif D.M., Xia M., Huang R., Judson R.S. Predictive endocrine testing in the 21st century using in vitro assays of estrogen receptor signaling responses. Environ. Sci. Technol. 2014, 10.1021/es502676e.
53. Safe S.H. Development validation and problems with the toxic equivalency factor approach for risk assessment of dioxins and related compounds. J. Anim. Sci. 1998, 76(1):134-141.
54. Setchell K.D.R., Faughnan M.S., Avades T., Zimmer-Nechemias L., Brown N.M., Wolfe B.E., Brashear W.T., Desai P., Oldfield M.F., Botting N.P., Cassidy A. Comparing the pharmacokinetics of daidzein and genistein with the use of 13C-labeled tracers in premenopausal women. Am. J. Clin. Nutr. 2003, 77:411-419.
55. Setchell K.D.R., Brown N.M., Zhao X., Lindley S.L., Heubi J.E., King E.C., Messina M.J. Soy isoflavone phase II metabolism differs between rodents and humans: implications for the effect on breast cancer risk. Am. J. Clin. Nutr. 2011, 94:1284-1294. 10.3945/ajcn.111.019638.
56. Shelnutt S.R., Cimino C.O., Wiggins P.A., Badger T.M. Urinary pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein. Cancer Epidemiol. Biomarkers Prev. 2000, 9:413-419.
57. Shelnutt S.R., Cimino C.O., Wiggins P.A., Ronis M.J.J., Badger T.M. Pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein in men and women after consumption of a soy beverage. Am. J. Clin. Nutr. 2002, 76:588-594.
58. Shimazu T., Inoue M., Sasazuki S., Iwasaki M., Sawada N., Yamaji T., Tsugane S., JPHC Study Group Plasma isoflavones and the risk of lung cancer in women: a nested case-control study in Japan. Cancer Epidemiol. Biomarkers Prev. 2011, 20:419-427.
59. Simons S.S., Kumar R. Variable steroid receptor responses: intrinsically disordered AF1 is the key. Mol. Cell. Endocrinol. 2013, 376:81-84. 10.1016/j.mce.2013.06.007.
60. Simon T.W., Simons S.S., Preston R.J., Boobis A.R., Cohen S.M., Doerrer N.G., Fenner-Crisp P.A., McMullin T.S., McQueen C.A., Rowlands J.C., RISK21 Dose-Response Subteam The use of mode of action information in risk assessment: quantitative key events/dose-response framework for modeling the dose-response for key events. Crit. Rev. Toxicol. 2014, 44(Suppl. 3):17-43. 10.3109/10408444.2014.931925.
61. Sipes N.S., Martin M.T., Kothiya P., Reif D.M., Judson R.S., Richard A.M., Houck K.A., Dix D.J., Kavlock R.J., Knudsen T.B. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem. Res. Toxicol. 2013, 26:878-895. 10.1021/tx400021f.
62. Slob W., Setzer R.W. Shape and steepness of toxicological dose-response relationships of continuous endpoints. Crit. Rev. Toxicol. 2014, 44:270-297. 10.3109/10408444.2013.853726.
63. Simons S.S. What goes on behind closed doors: physiological versus pharmacological steroid hormone actions. BioEssays 2008, 30:744-756. 10.1002/bies.20792.
64. Strassburg C.P., Strassburg A., Kneip S., Barut A., Tukey R.H., Rodeck B., Manns M.P. Developmental aspects of human hepatic drug glucuronidation in young children and adults C P 1,1. Gut 2002, 50:259-265. 10.1136/gut.50.2.259.
65. Takashima N., Miyanaga N., Komiya K., More M., Akaza H. Blood isoflavone levels during intake of a controlled hospital diet. J. Nutr. Sci. Vitaminol. (Tokyo) 2004, 50:246-252.
66. Teeguarden J., Hanson-Drury S., Fisher J.W., Doerge D.R. Are typical human serum BPA concentrations measurable and sufficient to be estrogenic in the general population?. Food Chem. Toxicol. 2013, 62:949-963. 10.1016/j.fct.2013.08.001.
67. Teeguarden J.G., Waechter J.M., Clewell H.J., Covington T.R., Barton H.A. Evaluation of oral and intravenous route pharmacokinetics, plasma protein binding, and uterine tissue dose metrics of Bisphenol A: a physiologically based pharmacokinetic approach. Toxicol. Sci. 2005, 85:823-838. 10.1093/toxsci/kfi135.
68. Teeguarden J.G., Calafat A.M., Ye X., Doerge D.R., Churchwell M.I., Gunawan R., Graham M.K. Twenty-four hour human urine and serum profiles of Bisphenol A during high-dietary exposure. Toxicol. Sci. 2011, 123:48-57. 10.1093/toxsci/kfr160.
69. Teeguarden J.G., Hanson-Drury S. A systematic review of Bisphenol A "low dose" studies in the context of human exposure: a case for establishing standards for reporting "low-dose" effects of chemicals. Food Chem. Toxicol. 2013, 62:935-948. 10.1016/j.fct.2013.07.007.
70. Thomas R.S., Black M., Li L., Healy E., Chu T.-M., Bao W., Andersen M., Wolfinger R. A comprehensive statistical analysis of predicting in vivo hazard using high-throughput in vitro screening. Toxicol. Sci. 2012, 128:398-417. 10.1093/toxsci/kfs159.
71. Thomas R.S., Philbert M.A., Auerbach S.S., Wetmore B.A., Devito M.J., Cote I., Rowlands J.C., Whelan M.P., Hays S.M., Andersen M.E., Meek M.E.B., Reiter L.W., Lambert J.C., Clewell H.J., Stephens M.L., Zhao Q.J., Wesselkamper S.C., Flowers L., Carney E.W., Pastoor T.P., Petersen D.D., Yauk C.L., Nong A. Incorporating new technologies into toxicity testing and risk assessment: moving from 21st century vision to a data-driven framework. Toxicol. Sci. 2013, 136:4-18. 10.1093/toxsci/kft178.
72. United States Environmental Protection Agency (USEPA). 2011. Endocrine Disruptor Screening Program for the 21st Century: (EDSP21 Workplan) The Incorporation of In Silico Models and In VitroHigh Throughput Assay in the Endocrine Disruptor Screening Program (EDSP) for Prioritization and Screening.
73. United States Environmental Protection Agency (USEPA). 2014. Exposure SAP White Paper: New High-throughput Methods to Estimate Chemical Exposure. http://www.regulations.gov/#!documentDetail;D=EPA-HQ-OPP-2014-0331-0005.
74. United States Environmental Protection Agency (USEPA). 2014b. Integrated Bioactivity and Exposure Ranking: A Computational Approach for the Prioritization and Screening of Chemicals in the Endocrine Disruptor Screening Program. http://www.regulations.gov/#!documentDetail;D=EPA-HQ-OPP-2014-0614.
75. Van den Berg M., Birnbaum L., Bosveld A.T., Brunstrom B., Cook P., Feeley M., Giesy J.P., Hanberg A., Hasegawa R., Kennedy S.W., Kubiak T., Larsen J.C., van Leeuwen F.X., Liem A.K., Nolt C., Peterson R.E., Poellinger L., Safe S., Schrenk D., Tillitt D., Tysklind M., Younes M., Waern F., Zacharewski T. Toxic equivalency factors (TEFs) for PCBs, PCDDs, PCDFs for humans and wildlife Environ. Health. Perspect. 1998, 106:775-792.
76. Van den Berg M., Birnbaum L.S., Denison M., De V.M., Farland W., Feeley M., Fiedler H., Hakansson H., Hanberg A., Haws L., Rose M., Safe S., Schrenk D., Tohyama C., Tritscher A., Tuomisto J., Tysklind M., Walker N., Peterson R.E. The 2005 World Health Organization reevaluation of human and Mammalian toxic equivalency factors for dioxins and dioxin-like compounds. Toxicol. Sci. 2006, 93:223-241.
77. Völkel W., Colnot T., Csanády G.A., Filser J.G., Dekant W. Metabolism and kinetics of bisphenol a in humans at low doses following oral administration. Chem. Res. Toxicol. 2002, 15:1281-1287.
78. Wambaugh J.F., Setzer R.W., Reif D.M., Gangwal S., Mitchell-Blackwood J., Arnot J.A., Joliet O., Frame A., Rabinowitz J., Knudsen T.B., Judson R.S., Egeghy P., Vallero D., Cohen Hubal E.A. High-throughput models for exposure-based chemical prioritization in the ExpoCast project. Environ. Sci. Technol. 2013, 47:8479-8488.
79. Wang S., Houtman R., Melchers D., Aarts J., Peijnenburg A., van Beuningen R., Rietjens I., Bovee T.F. A 155-plex high-throughput in vitro coregulator binding assay for (anti-)estrogenicity testing evaluated with 23 reference compounds. ALTEX 2013, 30:145-157.
80. Wetmore B.A., Wambaugh J.F., Ferguson S.S., Sochaski M.A., Rotroff D.M., Freeman K., Clewell H.J., Dix D.J., Andersen M.E., Houck K.A., Allen B., Judson R.S., Singh R., Kavlock R.J., Richard A.M., Thomas R.S. Integration of dosimetry, exposure and high-throughput screening data in chemical toxicity assessment. Toxicol. Sci. 2012, 125:157-174. 10.1093/toxsci/kfr254.
81. Wetmore B.A., Wambaugh J.F., Ferguson S.S., Li L., Clewell H.J., Judson R.S., Freeman K., Bao W., Sochaski M.A., Chu T.-M., Black M.B., Healy E., Allen B., Andersen M.E., Wolfinger R.D., Thomas R.S. Relative impact of incorporating pharmacokinetics on predicting in vivo hazard and mode of action from high-throughput in vitro toxicity assays. Toxicol. Sci. 2013, 132:327-346. 10.1093/toxsci/kft012.
82. Yoon M., Efremenko A., Blaauboer B.J., Clewell H.J. Evaluation of simple in vitro to in vivo extrapolation approaches for environmental compounds. Toxicol. In Vitro 2014, 28:164-170.
83. Yuan B., Zhen H., Jin Y., Xu L., Jiang X., Sun S., Li C., Xu H. Absorption and plasma disposition of genistin differ from those of genistein in healthy women. J. Agric. Food Chem. 2012, 60:1428-1436. 10.1021/jf204421c.
84. Zhang Y., Hendrich S., Murphy P.A. Glucuronides are the main isoflavone metabolites in women. J. Nutr. 2003, 133:399-404.
85. Zhang Z., Teng C.T. Estrogen receptor alpha and estrogen receptor-related receptor alpha1 compete for binding and coactivator. Mol. Cell. Endocrinol. 2001, 172:223-233.